Welcome to our dedicated page for Maravai Lifesciences Holdings SEC filings (Ticker: MRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Maravai LifeSciences Holdings, Inc. filings document the formal disclosures of a Nasdaq-listed life sciences operating company with Class A common stock. Form 8-K reports furnish quarterly and annual financial results, including revenue, net loss, adjusted EBITDA and business updates for the TriLink nucleic acid synthesis and Cygnus biologics safety testing operations.
The company’s proxy materials describe annual meeting matters, director elections, independent auditor ratification, executive compensation votes and board governance. Other current reports record leadership succession, board-size and committee changes, equity-award treatment, and restructuring actions classified as exit or disposal activities, including related cost disclosures and risk language.
MARAVAI LIFESCIENCES HOLDINGS, INC. director and Chief Executive Officer Bernd Brust reported routine share movements related to equity compensation. On June 8, 2026, 351,001 shares of Class A Common Stock were withheld at $5.02 per share to satisfy tax obligations from restricted stock unit vesting, which is not an open-market sale.
After these transactions, Brust directly owns 1,648,999 shares of Class A Common Stock and indirectly holds 466,771 shares through The Bernd Brust Management Trust, indicating a substantial remaining equity position in the company.
MARAVAI LIFESCIENCES HOLDINGS, INC. General Counsel Kurt Oreshack reported open-market sales of Class A Common Stock. He sold 25,000 shares on June 9, 2026 at $5.06 per share and 25,000 shares on June 10, 2026 at $5.10 per share. These transactions were effected under a pre-arranged Rule 10b5-1 trading plan. Following the sales, he directly holds 335,767 shares of Maravai Lifesciences stock.
Maravai Lifesciences Holdings director Gregory T. Lucier reported gifting 92,586 shares of Class A common stock. On June 9, 2026, he made two bona fide gift transfers of 46,293 shares each at $0.00 per share.
Following these gifts, Lucier holds 155,123 shares directly and 156,077 shares indirectly through a family partnership. According to the disclosure, the family partnership is managed by his spouse, and Lucier disclaims beneficial ownership of those partnership-held shares except to the extent of his pecuniary interest.
Kurt Oreshack reports intent to sell 25,000 Class A shares of MRVI. The Form 144 entry lists 25,000 shares and an aggregate figure of $127,500.00, with the filing dated 06/10/2026. The securities are described as resulting from Restricted Stock Vesting on 01/15/2025.
Maravai LifeSciences (MRVI) filed a Form 144 reporting an intent to sell 25,000 shares of Class A common stock through Fidelity Brokerage Services LLC on NASDAQ. The filing lists prior acquisitions of Class A shares by vesting and ESPP purchases on 03/15/2024, 04/30/2024, 10/31/2024, and 01/15/2025 totaling the disclosed prior receipts.
Maravai LifeSciences refinanced its main credit facilities through a new $150 million term loan and a $30 million revolving credit facility maturing on June 2, 2032. Subsidiaries Maravai Intermediate Holdings and Maravai Topco entered into the new credit agreement with a lender group.
Proceeds from the new term loan, plus about $98.5 million of cash on hand, were used to fully repay and terminate the prior credit agreement that was due in October 2027. The transaction reduces long-term debt from roughly $242.9 million of aggregate principal to $150.0 million and extends the company’s debt maturity profile.
Borrowings bear interest at Term SOFR plus 5.00% per annum, with a potential 0.25% stepdown tied to leverage, and carry customary covenants and events of default, including a financial covenant based on a consolidated first lien net leverage ratio.
Maravai LifeSciences Holdings, Inc. reported the results of its 2026 Annual Meeting of Shareholders. As of the March 27, 2026 record date, the company had 258,180,170 shares of common stock outstanding, including 147,496,090 Class A shares and 110,684,080 Class B shares.
Shareholders holding 236,082,968 shares were present in person or by proxy, establishing a quorum. Three directors — Bernd Brust, Gregory T. Lucier and Luke Marker — were elected to three-year terms ending at the 2029 Annual Meeting. Shareholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved on a non-binding advisory basis the compensation of the named executive officers.
LUCIER GREGORY T reported acquisition or exercise transactions in this Form 4 filing.
Maravai LifeSciences Holdings director Gregory T. Lucier reported an amended Form 4 showing an equity award and updated holdings. He received 46,293 shares of Class A Common Stock in the form of restricted stock units granted on May 26, 2026 at a grant price of $0.00 per share, awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan.
These restricted stock units vest in full on the earlier of one year from the grant date or the date of the 2027 annual meeting of stockholders. Following this award, Lucier directly owns 201,416 shares of Class A Common Stock and has an additional 109,784 shares held indirectly through a family partnership. The filing is also being amended to correct the purchase price previously reported on a Form 4 filed the same date.
MARKER LUKE JOSEPH reported acquisition or exercise transactions in this Form 4 filing.
MARAVAI LIFESCIENCES HOLDINGS, INC. reported that an entity affiliated with GTCR, associated with director Luke Joseph Marker, was awarded 46,293 restricted stock units of Class A Common Stock under the 2020 Omnibus Incentive Plan.
These restricted stock units vest in full on the earlier of one year from the May 26, 2026 grant date or the 2027 annual meeting of stockholders. Following the award, 184,348 shares are reported as held, which the reporting person holds for the benefit of the GTCR-affiliated entity while disclaiming any pecuniary interest or beneficial ownership for Section 16 purposes.
GRAY SUSANNAH reported acquisition or exercise transactions in this Form 4 filing.
MARAVAI LIFESCIENCES HOLDINGS, INC. director Susannah Gray received a grant of 46,293 shares of Class A Common Stock in the form of restricted stock units under the 2020 Omnibus Incentive Plan. Her direct holdings increased to 216,200 shares after this award, which vests in full after one year or at the 2027 annual meeting.